icell gene therapeutics LLC

2 white pine lane
e. setauket, new york 11733

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 05, 2014

NYS DOS ID#
4632201

County
SUFFOLK

Jurisdiction
NEW YORK

Registered Agent
YUPO MA
2 WHITE PINE LANE
E.SETAUKET, NEW YORK, 11733

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - ICELL GENE THERAPEUTICS LLC
2014 - I CELL GENE THERAPEUTICS LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
    By Ben Fidler - Wednesday Aug 9, 2017

    A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]

    Source: Xconomy New York
  • Dragonfly, eGenesis, Spero & More: Xconomy’s Startup Award Finalists
    By Corie Lok - Monday Aug 14, 2017

    Startups play a critical role in the innovation economy that we chronicle at Xconomy—transforming new ideas that begin in a lab into the products and companies of tomorrow. No surprise, then, that the startup category in our first-ever Awards program was a particularly competitive one, loaded with private companies (no more than 5 years old) […]

    Source: Xconomy New York
  • Bio Roundup: PDUFA Progress, BCRA Redux, CAR-T Thumbs Up, & More
    By Frank Vinluan - Friday Jul 14, 2017

    Government and industry are rife with awkward acronyms. Take PDUFA, for example. First passed in 1992, the Prescription Drug User Fee Act allows the FDA to collect fees from biopharmaceutical companies when they apply for drug approval; those funds are designated for the regulator’s drug evaluation work. Congress must reauthorize the law every five years […]

    Source: Xconomy New York
  • LogicBio Lands $45M for Gene Therapies in Rare Pediatric Diseases
    By Frank Vinluan - Wednesday Jun 28, 2017

    Gene therapy offers the potential for a long-lasting, if not permanent, treatment for an inherited disease, but cells that divide rapidly, such as those in the liver, present a thorny problem. Because of how they insert themselves in the cells, some forms of gene therapy get “diluted” as the cells divide. It’s a particular problem […]

    Source: Xconomy VC, Deals, & Startups Feed
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
icell gene therapeutics llc e setauket ny